The potential to improve Lyme disease diagnostics through quantification of immunoglobulin class switching patterns
Journal of Clinical Microbiology · 2025
DOI: 10.1128/jcm.01020-25 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of Clinical Microbiology, 2025. Verfasst von Anna M Schotthoefer. Beteiligte Einrichtung: Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, Wisconsin, USA. Hauptthemen laut MEDLINE: Lyme Disease, Antibodies, Bacterial, Borrelia burgdorferi, Immunoglobulin Isotypes. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
N. Nair, A. Marques , E. J. Horn, G. Brown et al., J Clin Microbiol 63:e0034725, 2025, https://doi.org/10.1128/jcm.00347-25 present data to demonstrate that infection by Borrelia burgdorferi , the primary causative agent of Lyme disease in the USA, leads to immunoglobulin class switching in antibodies specifically against the immunodominant antigen, VlsE (variable major protein-like sequence, expressed), in a predictable pattern between the early acute (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, Wisconsin, USA.
ORCID-Profile: Anna M Schotthoefer
Zitieren
APA
Schotthoefer, A. M. (2025). The potential to improve Lyme disease diagnostics through quantification of immunoglobulin class switching patterns. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01020-25
Vancouver
Schotthoefer AM. The potential to improve Lyme disease diagnostics through quantification of immunoglobulin class switching patterns. Journal of Clinical Microbiology. 2025. doi:10.1128/jcm.01020-25
BibTeX
@article{Schotthoefer2025,
author = {Schotthoefer, Anna M},
title = {The potential to improve Lyme disease diagnostics through quantification of immunoglobulin class switching patterns},
journal = {Journal of Clinical Microbiology},
year = {2025},
doi = {10.1128/jcm.01020-25}
}
EUVIMED